Protein biomarkers in cancer include overexpressed proteins (e.g., HER2), mutated proteins (including neoantigens and products of gene fusions), or proteins with tumor-specific post-translational modifications (e.g., glycoproteins), all of which can be detected in tumor tissue. Here, ERBB2 is linked to neoplasm.